.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Nabumetone - Generic Drug Details

« Back to Dashboard
Nabumetone is the generic ingredient in two branded drugs marketed by Par Pharm, Mylan Pharms Inc, Dr Reddys Labs Ltd, Apotex Inc, Lupin Ltd, Invagen Pharms, Copley Pharm, Sandoz, Watson Labs, Smithkline Beecham, Impax Labs Inc, and Oxford Pharms, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty drug master file entries for nabumetone. Forty suppliers are listed for this compound.

Summary for Generic Name: nabumetone

Tradenames:2
Patents:0
Applicants:12
NDAs:13
Drug Master File Entries: see list20
Suppliers / Packaging: see list40
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices

Pharmacology for Ingredient: nabumetone

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd
NABUMETONE
nabumetone
TABLET;ORAL090445-002Jan 12, 2011RXNo► subscribe► subscribe
Sandoz
NABUMETONE
nabumetone
TABLET;ORAL075590-002Feb 25, 2002DISCNNo► subscribe► subscribe
Invagen Pharms
NABUMETONE
nabumetone
TABLET;ORAL078671-001Mar 7, 2008RXNo► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: nabumetone

These historical archives are available as an add-on to one-year subscriptions.
See the Subscription Options for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Smithkline Beecham
RELAFEN
nabumetone
TABLET;ORAL019583-001Dec 24, 19914,061,779► subscribe
Smithkline Beecham
RELAFEN
nabumetone
TABLET;ORAL019583-002Dec 24, 19914,420,639*PED► subscribe
Smithkline Beecham
RELAFEN
nabumetone
TABLET;ORAL019583-002Dec 24, 19914,061,779► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc